Active substanceKetorolacKetorolac
Similar drugsTo uncover
  • Akyular LS
    drops d / eye 
    Allergen, Inc.     USA
  • Vatorlak
    solution w / m in / in 
    Novator Pharma, LLC     United Kingdom
  • Dolac
    solution w / m in / in 
  • Dolac
    pills inwards 
  • Dolomin®
    solution w / m in / in 
  • Cetadrope®
    drops d / eye 
  • Ketalgin®
    pills inwards 
  • Ketalgin®
    solution w / m in / in 
  • Ketanov®
    pills inwards 
  • Ketanov®
    solution w / m 
  • Ketokam®
    pills inwards 
  • Ketolac®
    solution w / m in / in 
    ALTAYVITAMINS, CJSC     Russia
  • Ketolac®
    pills inwards 
    ALTAYVITAMINS, CJSC     Russia
  • Ketorol®
    solution w / m in / in 
  • Ketorol®
    gel externally 
  • Ketorol®
    pills inwards 
  • Ketorolac
    pills inwards 
    VERTEKS, AO     Russia
  • Ketorolac
    solution w / m in / in 
  • Ketorolac
    pills inwards 
  • Ketorolac
    solution w / m 
  • Ketorolac
    solution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Ketorolac
    pills inwards 
  • Ketorolac
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Ketorolac
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Ketorolac
    pills inwards 
    LEKHIM-KHARKOV, CJSC     Ukraine
  • Ketorolac
    pills inwards 
  • Ketorolac
    solution w / m in / in 
  • Ketorolac
    solution w / m 
    TRIVIUM-XXI, LLC     Russia
  • Ketorolac
    solution w / m in / in 
  • Ketorolac
    solution w / m 
  • Ketorolac - SOLOFARM
    solution w / m in / in 
    GROTEKS, LLC     Russia
  • Ketorolac Rhompharm
    solution w / m in / in 
  • Ketorolac-OBL
    pills inwards 
  • Ketorolak-Eskom
    solution w / m in / in 
    ESKOM NPK, OAO     Russia
  • Ketofril®
    pills inwards 
  • Ketofril®
    solution w / m in / in 
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    1 ml of the solution contains:

    aactive substance: ketorolac trometamol (ketorolac tromethamine) 30.0 mg;

    atExcipients: ethanol 95% 100.0 mg, sodium chloride 4.35 mg, sodium hydroxide 1 M solution or hydrochlorideof a native acid of 1 M solution up to pH 6.9-7.9, water for injection up to 1 ml.

    Description:

    Transparent liquid of light yellow color.

    Pharmacotherapeutic group:Non-steroidal anti-inflammatory drug (NSAID)
    ATX: & nbsp

    M.01.A.B.15   Ketorolac

    Pharmacodynamics:

    Non-steroidal anti-inflammatory drug (NSAID). Has a pronounced analgesic effect, has anti-inflammatory and moderate antipyretic effect. The mechanism of action is associated with a nonselective inhibition of cyclooxygenase-1 and cyclooxygenase-2 activity catalyzing the formation of prostaglandins (Pg) from arachidonic acid, which play an important role in the pathogenesis of pain, inflammation and fever. By the strength of the analgesic effect comparable to morphine, it significantly exceeds other NSAIDs.

    Pharmacokinetics:

    After intramuscular injection, the onset of analgesic action occurs after 30 minutes, the maximum effect is achieved after 1-2 hours. The maximum accumulation in tissues (CmOh) 30 mg - 1.74-3.1 μg / ml, 60 mg - 3.23-5.77 μg / ml, The period of reaching the maximum concentration (TFROMmOh) - 15-73 min. FROMmOh after intravenous infusion 15 mg - 1.96-2.98 mcg / ml, 30 mg - 3.69-5.61 mcg / ml. The connection with plasma proteins is 99%.

    Time to reach equilibrium concentration (CSS) - 24 hours when administered 4 times a day (higher than sub-therapeutic) and is 15 mg-0.65-1.13 μg / ml for intramuscular injection, 30 mg-1.29-2.47 μg / ml, with intravenous infusion 15 mg to 0.79 to 1.39 μg / ml, 30 mg to 1.68 to 2.76 μg / ml. The volume of distribution is 0.15-0.33 l / kg. In patients with renal insufficiency, the volume of distribution of the drug can be increased 2-fold, and the volume of its distribution R-enantiomer by 20%. Penetrates into breast milk, when the mother is taken 10 mg ketorolac FROMmOh in milk is achieved through 2 h after the first dose and is 7.3 ng / ml, 2 hours after the second dose of ketorolac (using the drug 4 times a day) - 7.9 ng / l.

    More than 50% of the administered dose is metabolized in the liver with the formation of pharmacologically inactive metabolites. The main metabolites are glucuronides, which are excreted by the kidneys, and p-hydroxycetorolac.

    It is excreted on 91 kidneys, 6% - through the intestine. The half-life (T1/2) In patients with normal renal function - on average 5.3 h (3,5-9,2 hours after intramuscular injection of 30 mg, 4-7,9 hours after intravenous administration of 30 mg of T.1/2 increases in elderly patients and is shortened in young people. The function of the liver does not affect T1/2. In patients with impaired renal function with a creatinine concentration in the plasma of 19-50 mg / l (168-442 μmol / L) T1/2 - 10,3-10,8 h, more renal failure -. More than 13.6 hours Total clearance is by intramuscular administration of 30 mg - 0.023 L / h / kg (0,019 l / h / kg in the elderly), intravenous infusion of 30 mg - 0.03 l / h / kg; patients with renal failure at a plasma creatinine concentration of 19-50 mg / l after intramuscular administration of 30 mg - 0.015 L / h / kg.

    It is not excreted by hemodialysis.

    Indications:

    Pain syndrome of strong and moderate severity: trauma, toothache, pain in the postoperative period, oncological diseases, myalgia, arthralgia, neuralgia, sciatica, dislocations, sprains, rheumatic diseases.

    Designed for symptomatic therapy, reducing pain and inflammation at the time of use; on the progression of the disease is not affected.

    Contraindications:

    Hypersensitivity to the active substance or ancillary components. Complete or incomplete combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs (including in the anamnesis), urticaria, rhinitis caused by the intake of NSAIDs (in the anamnesis); intolerance to drugs of pyrazolone series, hypovolemia (regardless of the cause), erosive and ulcerative lesions of the gastrointestinal tract in the acute stage, hypocoagulation (including hemophilia), bleeding or a high risk of their development, severe renal failure (creatinine clearance less than 30 ml / min), severe hepatic insufficiency or active liver disease, condition after aortocoronary shunting, confirmed hyperkalemia, pregnancy (III trimester), inflammatory bowel disease, childbirth period, lactation period, children under 16 years of age (safety and efficacy not established).

    Carefully:

    Bronchial asthma, the presence of factors that increase toxicity in relation to the gastrointestinal tract (GIT): alcoholism and cholecystitis; chronic heart failure, edematous syndrome,arterial hypertension, impaired renal function, cholestasis, active hepatitis, sepsis, simultaneous intake with other NSAIDs, advanced age (over 65 years), pregnancy (I-II trimester).

    Ischemic heart disease, cerebrovascular disease, congestive heart failure, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, creatinine clearance less than 60 ml / min.

    Anamnestic data on the development of gastrointestinal lesions, the presence of infection Helicobacter pylori, long-term use of NSAIDs, severe somatic diseases, concomitant therapy with the following drugs:

    - anticoagulants (incl. warfarin);

    - antiaggregants (incl. acetylsalicylic acid, clopidogrel);

    - selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline);

    - glucocorticoids (incl. prednisolone).

    To reduce the risk of developing adverse events on the part of the gastrointestinal tract, a minimum effective dose should be used with the minimum possible short course.

    Pregnancy and lactation:

    It penetrates into breast milk in small amounts.

    Application in III trimester of pregnancy and when breastfeeding is contraindicated (should be abandoned from feeding for the period of application of the drug).

    In extreme cases, if you need to use the drug during pregnancy and breastfeeding, you should compare the benefits to the mother and the risk to the fetus or the baby.
    Dosing and Administration:

    Intramuscularly, intravenously.

    When administered intravenously, the dose should be administered at least 15 seconds (for dosage forms containing ethanol).

    Patients from 16 to 64 years of age with a body weight exceeding 50 kg, intramuscularly for 1 administration is administered not more than 60 mg (including oral dose); usually 30 mg every 6 hours, intravenously - 30 mg (not more than 15 doses per 5 days).

    Intramuscularly, for adults with a body weight of less than 50 kg or with chronic renal failure (CRF), no more than 30 mg (including oral dose) is administered per administration; usually - 15 mg (no more than 20 doses per 5 days); in / in - no more than 15 mg every 6 hours (no more than 20 doses in 5 days).

    The maximum daily doses for intramuscular and intravenous administration are for patients from 16 to 64 years with a body weight exceeding 50 kg, 90 mg / day; adult patients with a body weight of less than 50 kg or with CRF, as well as elderly patients (over 65 years of age) - for intramuscular and intravenous administration of 60 mg.The duration of treatment should not exceed 5 days.

    Side effects:

    Often - more than 3%, less often - 1-3%, rarely - less than 1%.

    From the digestive system: often - gastralgia, diarrhea; less often - stomatitis, flatulence, constipation, vomiting, sensation of stomach overflow; rarely - decreased appetite, nausea, erosive and ulcerative lesions of the digestive tract (including with perforation and / or bleeding - abdominal pain, spasm or burning in the epigastric region, blood in the feces or melena, vomiting with blood or the type of "coffee thick, "nausea, heartburn, etc.), cholestatic jaundice, hepatitis, hepatomegaly, acute pancreatitis.

    From the urinary system: rare - acute renal failure, back pain, hematuria, azotemia, hemolytic uremic syndrome (hemolytic anemia, renal failure, thrombocytopenia, purpura), frequent urination, increase or decrease in urine volume, nephritis, edema of renal genesis.

    From the sense organs: rarely - hearing loss, ringing in the ears, visual impairment (including blurred vision).

    From the respiratory system: rarely - bronchospasm or dyspnoea, rhinitis, pulmonary edema, laryngeal edema (shortness of breath, difficulty breathing).

    From the central nervous system (CNS): often - headache, dizziness, drowsiness; rarely - aseptic meningitis (fever, severe headache, cramps, stiffness in the neck muscles and / or back), hyperactivity (mood changes, anxiety), hallucinations, depression, psychosis, fainting.

    From the side of the cardiovascular system: less often - increased blood pressure.

    On the part of the organs of hematopoiesis: rarely - anemia, eosinophilia, leukopenia.

    From the side of the hemostasis system: rarely - bleeding from a postoperative wound, epistaxis, rectal bleeding.

    From the skin: less often - skin rash (including maculopapular rash), purpura; rarely exfoliative dermatitis (fever with chills or without, hyperemia, densification or flaking of the skin, enlargement and / or soreness of the tonsils), urticaria, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome).

    Local reactions: less often - burning or pain at the injection site.

    Allergic reactions: rarely - anaphylaxis or anaphylactoid reactions (skin color change of the face, skin rash, hives, itching of the skin,tachypnea or dyspnoea, edema of the eyelids, periorbital edema, shortness of breath, shortness of breath, heaviness in the chest, wheezing).

    Other: often - swelling (face, legs, ankles, fingers, feet, weight gain); less often - increased sweating, rarely - fever.

    Overdose:

    Symptoms (with a single administration): abdominal pain, nausea, vomiting, erosive-ulcerative gastrointestinal lesion, renal dysfunction, metabolic acidosis

    Treatment: symptomatic (maintenance of vital body functions).

    Dialysis is ineffective.

    Interaction:

    Co-administration with paracetamol increases the nephrotoxicity of ketorolac. Admission with other NSAIDs, glucocorticosteroids, ethanol, corticotropin, calcium preparations increases the risk of ulceration of the gastrointestinal mucosa and the development of gastrointestinal bleeding.

    Simultaneous appointment with anticoagulant drugs (LS) - derivatives of coumarin and indanedione, heparin, thrombolytics (alteplase, streptokinase, urokinase), antiplatelet drugs, cephalosporins, valproic acid and aminosalicylic acid increases the risk of bleeding.

    Reduces the effect of hypotensive and diuretics (reduces synthesis Pg in the kidneys).

    The appointment together with methotrexate increases hepato- and nephrotoxicity (their joint appointment is possible only with the use of low doses of the latter and control of its concentration in the plasma).

    When prescribed with other nephrotoxic drugs (including with drugs of gold), the risk of developing nephrotoxicity increases.

    LS, which block tubular secretion, reduce the clearance of ketorolac and increase its concentration in the plasma.

    Increases the effect of narcotic analgesics.

    Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

    Special instructions:

    Before prescribing the drug, it is necessary to clarify the question of the previous allergy to the drug or NSAIDs. Because of the risk of developing allergic reactions, the first dose is administered under close supervision of the doctor.

    Hypovolemia increases the risk of developing nephrotoxic adverse reactions.

    If necessary, you can prescribe in combination with narcotic analgesics.

    It is not recommended to be used as a medicine for premedication, maintenance of anesthesia.

    When combined with other NSAIDs, fluid retention, cardiac decompensation, and elevated blood pressure (BP) may occur. The effect on platelet aggregation stops after 24-48 hours. Do not use simultaneously with paracetamol for more than 5 days.

    Patients with blood clotting disorder are appointed only with a constant control of the number of platelets, it is especially important for postoperative patients requiring careful control of hemostasis.

    The risk of developing drug complications increases with prolonged treatment (in patients with chronic pain) and an increase in the dose of the drug.

    To reduce the risk of developing NSAIDs, gastropathies are prescribed misoprostol, omeprazole.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:Solution for intravenous and intramuscular injection 30 mg / ml.
    Packaging:

    1 ml of the drug in ampoules.

    For 5 or 10 ampoules in a contour cell package.

    For 1 or 2 contour packs with instructions for use in a cardboard box.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-004693/09
    Date of registration:10.06.2009
    Expiration Date:Unlimited
    The owner of the registration certificate:ESKOM NPK, OAO ESKOM NPK, OAO Russia
    Manufacturer: & nbsp
    Representation: & nbspESKOM NPK, OAOESKOM NPK, OAO
    Information update date: & nbsp07.01.2018
    Illustrated instructions
      Instructions
      Up